Representative Lisa C. McClain (R-Michigan) recently sold shares of Boston Scientific Corporation NYSE: BSX. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on August 4th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.
Representative Lisa C. McClain also recently made the following trade(s):
- Sold $50,001 - $100,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 8/28/2025.
- Purchased $1,001 - $15,000 in shares of ACI Worldwide NASDAQ: ACIW on 8/19/2025.
- Purchased $1,001 - $15,000 in shares of HCA Healthcare NYSE: HCA on 8/19/2025.
- Sold $1,001 - $15,000 in shares of Amedisys NASDAQ: AMED on 8/18/2025.
- Purchased $1,001 - $15,000 in shares of Kite Realty Group Trust NYSE: KRG on 8/13/2025.
- Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/13/2025.
- Purchased $1,001 - $15,000 in shares of JD.com NASDAQ: JD on 8/13/2025.
- Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 8/13/2025.
- Sold $1,001 - $15,000 in shares of US Foods NYSE: USFD on 8/13/2025.
- Purchased $1,001 - $15,000 in shares of Agree Realty NYSE: ADC on 8/13/2025.
Boston Scientific Stock Down 0.4%
Shares of Boston Scientific stock traded down $0.39 during midday trading on Friday, hitting $97.84. The company's stock had a trading volume of 16,833,754 shares, compared to its average volume of 8,034,038. The firm has a market capitalization of $144.97 billion, a P/E ratio of 58.24, a PEG ratio of 2.36 and a beta of 0.65. The stock has a 50-day simple moving average of $104.40 and a 200-day simple moving average of $102.11. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.
Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on BSX shares. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Needham & Company LLC reaffirmed a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a report on Friday. UBS Group upped their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Leerink Partners started coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target on the stock. Finally, Robert W. Baird upped their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $118.04.
Check Out Our Latest Stock Analysis on BSX
Insider Transactions at Boston Scientific
In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Boston Scientific
A number of hedge funds have recently modified their holdings of the business. HM Payson & Co. boosted its position in shares of Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. Riverwater Partners LLC raised its stake in Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock valued at $333,000 after buying an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management raised its stake in Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock valued at $291,000 after buying an additional 99 shares during the last quarter. IVC Wealth Advisors LLC raised its stake in shares of Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock worth $236,000 after purchasing an additional 102 shares during the last quarter. Finally, Park Square Financial Group LLC raised its stake in shares of Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 103 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.
About Representative McClain
Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election.
Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.
Boston Scientific Company Profile
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
